Curatis Holding AG Secures CHF 1.2 Million Investment for Drug Development

Curatis Holding AG has announced a CHF 1.2 million private placement agreement with a strategic Swiss investor. This convertible instrument will be transformed into shares of Curatis, provided under current market conditions. The completion of the transaction is anticipated shortly, pending standard approvals.

The investment aims to expedite the clinical development of Curatis' leading product candidate, corticorelin. This financial boost highlights the company's strategic push in the pharmaceutical sector, focusing on orphan and specialized drug products.

Curatis, a publicly traded entity on the SIX Swiss Exchange, boasts a substantial portfolio of over 40 products. The company is committed to addressing rare and very rare diseases through its developmental and commercial efforts.